11 studies found for:    alpharadin | Open Studies
Show Display Options
Rank Status Study
1 Recruiting A Study of Alpharadin® With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)
Conditions: Bone Metastases;   Castration-Resistant Prostate Cancer
Interventions: Drug: Alpharadin® (Radium-223 dichloride) + docetaxel;   Drug: Docetaxel
2 Recruiting Re-treatment Safety of Radium-223 Dichloride in Castration-resistant Prostate Cancer With Bone Metastases
Condition: Prostatic Neoplasms
Intervention: Drug: Radium-223 dichloride (Xofigo, BAY88-8223)
3 Recruiting Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases
Condition: Prostatic Neoplasms
Intervention: Drug: Radium-223 dichloride (BAY88-8223)
4 Recruiting Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms
Condition: Prostatic Neoplasms
Interventions: Drug: Radium-223 dichloride (Xofigo, BAY88-8223);   Drug: Matching placebo (normal saline);   Drug: Abiraterone;   Drug: Prednisone/Prednisolone
5 Recruiting A Randomized Phase IIa Efficacy and Safety Study of
Condition: Prostatic Neoplasms
Interventions: Drug: Radium-223 dichloride (Xofigo,BAY88-8223);   Drug: Abiraterone acetate;   Drug: Prednisone;   Drug: Enzalutamide
6 Recruiting Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the Bone
Condition: Prostatic Neoplasms
Intervention: Drug: Radium-223 dichloride (Xofigo, BAY88-8223)
7 Recruiting Radium-223 Dichloride (Ra-223 Cl2) Asian Population Study in the Treatment of CRPC Patients With Bone Metastasis
Condition: Prostatic Neoplasms
Intervention: Drug: Radium-223 dichloride (Xofigo, BAY88-8223)
8 Recruiting Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma
Condition: Sarcoma
Intervention: Drug: Ra-223 Dichloride
9 Recruiting Japanese BAY88-8223 Monotherapy Phase II Study
Condition: Prostatic Neoplasms
Intervention: Drug: Radium-223 dichloride (Xofigo, BAY88-8223)
10 Recruiting Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis
Condition: Prostate Cancer
Intervention: Drug: Concurrent use of Radium Ra 223 dichloride and Abiraterone Acetate plus Prednisone
11 Recruiting A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)
Condition: Prostate Cancer
Intervention: Drug: PSMA ADC

Indicates status has not been verified in more than two years